| 2018-WON-68028 | |
| Over 60,000 new cases of head and neck cancer were diagnosed within the US in 2016, with 20 percent of these cases resulting in death. The current treatment of advanced head and neck cancer involves surgery followed by radiation, i.e. concurrent radiation, systemic chemotherapy, induction chemotherapy, or radiation alone. However, the surgeries are difficult, and radiation therapy afterwards is beneficial only for a few months. Conventional chemotherapy involves administering drugs through veins into the bloodstream, which involves high levels of toxicity and specific eligibility requirements. In addition, only 5 percent of the drug actually reaches the tumor site. There is need of a method for treating locally advanced tumors more effectively. Researchers at Purdue University have developed a radiation-controlled drug release formulation. The formulation allows toxicity and side effects associated with radiation from chemotherapy to be minimized by co-encapsulating the drug within protective capsules and injecting the solution into the patient's tumor before receiving normal radiotherapy. The release rate of the drug is controlled by radiation dose and frequency, allowing maintained drug concentration within the therapeutic level and toxic threshold over an extended period of time. This technology would be used to help medical/surgical/radiation/interventional oncologists who want to apply chemo-radiotherapy to cancer patients with tumors safely and effectively without compromising their quality of life. Advantages: -Controlled drug release -Minimized toxicity -Effectiveness -Longer lifespan Potential Applications: -Chemo-radiotherapy Related Publication: Radioluminescent nanoparticles for radiation-controlled release of drugs https://doi.org/10.1016/j.jconrel.2019.04.033 |
|
|
|
|
Mar 2, 2020
NATL-Patent
United States
(None)
(None)
Feb 18, 2020
NATL-Patent
Canada
(None)
(None)
Feb 11, 2020
NATL-Patent
Europe
(None)
(None)
Sep 7, 2018
PCT-Patent
WO
(None)
(None)
Sep 8, 2017
Provisional-Patent
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |
